Explore more Johnson & Johnson sites:
Share
Download Report
Back to top
= Achieved
Pharmaceutical Pipeline – Key Events in 2022*
POTENTIAL APPROVALS US/EU
CARVYKTI (Ciltacabtagene autoleucel)
Relapsed Refractory Multiple Myeloma
US
EU
IMBRUVICA (ibrutinib)
Frontline Chronic Lymphocytic Leukemia (I + V fixed duration) (GLOW)
EU
IMBRUVICA (ibrutinib)
Pediatric Chronic Graft Versus Host Disease
US
teclistamab (BCMA/CD3)
Relapsed Refractory Multiple myeloma
US
EU
CABENUVA
HIV Adolescents
US
STELARA (ustekinumab)
Pediatric Juvenile Psoriatic Arthritis
US
PLANNED SUBMISSIONS US/EU
IMBRUVICA (ibrutinib)
Treatment naïve patients with Mantle Cell Lymphoma in combination with Bendamustine and Rituximab (SHINE)
EU
teclistamab (BCMA/CD3)
Relapsed Refractory Multiple myeloma
EU
IMBRUVICA (ibrutinib)
Pediatric Chronic Graft Versus Host Disease
US
niraparib
L1 Prostate cancer metastatic castration-resistant in combination with abiraterone acetate and Prednisone
EU
talquetamab
Relapsed Refractory Multiple myeloma
US
ERLEADA (apalutamide)
Tablet Reduction
US
EU
aprocitentan
Difficult to treat hypertension
US
POTENTIAL CLINICAL DATA
Phase III
niraparib
L1 Prostate cancer metastatic castration-resistant (MAGNITUDE)
aprocitentan
Difficult to treat hypertension (PRECISION RHTT)
Phase II
BALVERSA (erdafitinib)
Tumor Agnostic (RAGNAR)
milvexian (factor Xla)
Secondary stroke prevention (AXIOMATIC-SSP)
guselkumab/golimumab
Ulcerative Colitis (VEGA)
guselkumab
Ulcerative Colitis Monotherapy (QUASAR)
talquetamab
Relapsed Refractory Multiple Myeloma
*This information is accurate as of January 24, 2023 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.